#United States #New York #Class Action #Gross Law Firm #Regeneron Pharmaceuticals

Important Notice for Regeneron Pharmaceuticals Investors

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shareholders should take note that a class action lawsuit has been initiated against the company. The Gross Law Firm has issued a notification encouraging investors who purchased shares during the specified class period to come forward, especially given the upcoming deadline for appointing lead plaintiffs.

Key Details of the Lawsuit

The class period in question spans from November 2, 2023, to October 30, 2024. During this time, allegations have surfaced that Regeneron allegedly misled investors through significant omissions and false statements. Such allegations include failures to disclose crucial information regarding their pricing and sales practices related to one of their primary medications, Eylea.

Three key allegations stand out:
1. Conditional Payments to Distributors: It is alleged that Regeneron made undisclosed payments to distributors, stipulating they would not charge Eylea customers higher fees when using credit cards.
2. Price Concessions: These payments apparently allowed Regeneron to maintain a competitive edge by providing price concessions that were not transparently reported, resulting in misleading sales figures.
3. Violation of Federal Regulations: By not accurately reporting these financial practices, Regeneron purportedly violated the False Claims Act. This raised serious questions regarding the integrity of their reported sales figures.

Urgent Action Required

Shareholders who find themselves affected by these allegations are strongly encouraged to seek registration to be a part of the class action. The deadline to act is set for March 10, 2025. Any delays may hinder your ability to participate in potential recoveries.

To register, please visit: Gross Law Firm Registration. As part of the registration, you will gain access to a portfolio monitoring service that provides updates on the lawsuit’s progression.

Why Choose the Gross Law Firm?

The Gross Law Firm is well-regarded nationally for its extensive work in class action cases. The firm dedicates itself to protecting the rights of investors who have suffered damage due to deceitful business practices or fraud. By ensuring companies adhere to responsible practices, the firm works to facilitate fair recoveries for shareholders whose investments were impacted by misleading information.

To discuss your rights further, you can contact the Gross Law Firm directly:

• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: info@grosslawfirm.com
• - Phone: (646) 453-8903

Final Takeaway

This is a critical moment for shareholders of Regeneron Pharmaceuticals. With the allegations indicating a systematic misrepresentation of the company’s financials during a crucial period, timely action can prove essential for involved investors. Don’t let this opportunity pass; ensure your rights and interests are preserved by registering now and consulting with legal professionals about your options.